LoQus23 Therapeutics Appoints Dr. Cyrus Mozayeni as Chair
LoQus23 Therapeutics Ltd, a pioneering private biotechnology entity, has officially appointed Dr. Cyrus Mozayeni as the Chair of its Board of Directors. This decision underscores the firm's commitment to accelerating innovative treatments, specifically targeting Huntington's Disease and similar conditions associated with pathogenic triplet expansions.
Dr. Mozayeni arrives at LoQus23 equipped with extensive expertise in biotech corporate strategy and business development. His ability to navigate complex corporate landscapes is expected to provide invaluable insight as the company progresses from a recent successful fundraising campaign.
Exciting Developments After Successful Fundraising
This appointment comes on the heels of LoQus23's successful £35 million Series A funding round which was completed recently. The funds have empowered the company to push forward with clinical developments of its MSH3 inhibitors, which are designed to treat patients suffering from Huntington's Disease.
Dr. Mozayeni is currently the CEO of Pheon Therapeutics, where he has been instrumental in leading various growth initiatives, including a prominent Series B financing that raised $120 million earlier. His track record in the biotech industry spans over two decades and is characterized by a relentless pursuit of scientific advances and robust business growth.
Leadership Insights from LoQus23
Dr. David Reynolds, the CEO of LoQus23, shared his thoughts on Dr. Mozayeni's appointment. He mentioned that the appointment comes at a pivotal moment for the company. As they embark on their IND-enabling studies, Dr. Mozayeni’s world-class expertise will be paramount in guiding the team through crucial developments aimed at unveiling treatments for Huntington's Disease and other associated disorders.
In his own words, Dr. Mozayeni expressed tremendous enthusiasm about his new role. He stated that the scientific foundation of LoQus23's unique therapeutic approach shows great promise. He emphasized the importance of recent high-profile research that supports the need for targeted treatments against somatic CAG repeat expansions, affirming his commitment to advancing this groundbreaking work into clinical applications.
A Proven Track Record in Biotech
Dr. Cyrus Mozayeni's previous endeavors exemplify his capability in steering biotech companies towards success. He has an impressive history, having served as the President & CEO of Vedere Bio, which he helped launch during his tenure at Atlas Venture.
His early career saw him co-found CODA Biotherapeutics and Oncorus, where he contributed significantly to the companies’ strategic direction and operational execution. Furthermore, his leadership at Bluebird Bio played a substantial role in advancing a clinical-stage CAR T-cell program, showcasing his skills in both domain expertise and management acumen.
The Unique Approach of LoQus23 Therapeutics
LoQus23 Therapeutics is innovating treatments for Huntington’s Disease, a neurodegenerative disorder that currently impacts around 30,000 patients across the U.S. The company’s focus lies in developing small molecule drugs aimed at addressing genetic instability linked to the disease.
The firm's strategy is centered around a structure-based design approach, which can lead to more practical administration options compared to traditional therapies. Oral small molecule treatments stand to provide greater convenience, which is critical for patients grappling with chronic conditions like Huntington's Disease.
LoQus23's leading program, an allosteric MSH3 inhibitor, is poised to enter clinical trials in the near future. Given the organization's deep scientific expertise and dedicated leadership, the future looks promising as they advance these groundbreaking investigations.
About LoQus23 Therapeutics Ltd
LoQus23 Therapeutics Ltd is on a mission to alter the treatment landscape for Huntington's Disease and similar triplet repeat disorders. The firm emerged in 2019, founded by leading figures in the biotech sector including Dr. David Reynolds, and has a vision of transforming patient care through innovative mechanisms aimed at halting disease progression.
Noteworthy is the support from significant partners and investors, including SV Health Investors and Novartis Venture Fund, securing robust backing that fuels their ambitious goals. LoQus23's team, consisting of seasoned professionals in biotech, is eager to translate their scientific innovations into therapeutic realities that could dramatically improve patient outcomes.
Frequently Asked Questions
What does Dr. Cyrus Mozayeni bring to LoQus23 Therapeutics?
Dr. Mozayeni brings over 20 years of experience in biotech, focusing on corporate strategy and business development to help advance the company’s objectives.
Why is the recent funding round significant for LoQus23?
The £35 million Series A funding is vital as it enables LoQus23 to advance its clinical studies for MSH3 inhibitors aimed at treating Huntington's Disease.
How does LoQus23 plan to treat Huntington's Disease?
LoQus23 aims to treat Huntington's Disease by developing small molecule drugs that target DNA instability associated with the disease.
When is LoQus23's leading program entering clinical trials?
The lead program, an allosteric small molecule MSH3 inhibitor, is expected to enter clinical trials in 2026.
What is the focus of LoQus23’s current research?
The focus is on small molecule somatic expansion inhibitors that may treat Huntington's Disease and other triplet repeat expansion diseases effectively.
